The European AIDS Vaccine Initiative (EAVI2020) are getting closer to developing a protective vaccine against HIV with clinical trials now underway. Prof Quentin Sattentau, Jenner Investigator, is a member of the consortium coordinated by Prof Robin Shattock, Imperial College London. The role of Prof Sattentau’s lab is to design novel methods for stabilising HIV surface proteins with the aim of promoting enhanced antibody responses to vaccination.
Interview with Jenner Investigator, Prof Helen McShane in Horizon, the EU Research & Innovation magazine: "Several new TB vaccines are under development and there is growing optimism that a new vaccine will emerge. This could save millions of lives, but more work is needed to reassure the general public that vaccines are safe and effective. In the year 2000, there were no new TB vaccines in clinical trials. Today there are over a dozen – many of them coming from the TBVAC European consortium of vaccine developers".
HLA-E: exploiting pathogen-host interactions for vaccine development. Clin Exp Immunol. Article
Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays. Sci Rep, 9 (1), pp. 5596. Article
Clinical trials are an essential part of vaccine development, and our volunteers play a critical role in our studies.
If you would like to find out more about paid clinical trials, and what is involved in participating, please go to our Recruiting Trials page to see which trials are currently recruiting.
Dr Patrick Soentjens: Simplifying rabies pre- and post-exposure prophylaxis, 16/May/2019 13:00
Prof Mark Howarth: Spy and Snoop protein superglues applied to vaccine development, 19/Jul/2019 14:00